Ajanta Pharma Limited Q2 FY26 Concall Decoded:₹350 crore dividend declared, US growth on steroids, margins held hostage by ambition

1. Opening Hook

While most pharma CEOs were busy blaming price erosion and regulators, Ajanta Pharma casually dropped a ₹28 per share interim dividend and moved on. No drama. No sob story. Just a quiet flex.

Q2 FY26 wasn’t about survival—it was about control. Control over margins, growth levers, and geographic mix. The US suddenly woke up, Asia behaved, Africa took a breather, and India did what it does best—steady compounding.

Expenses rose, margins refused to collapse, and management made it clear: growth will always come before cosmetic margin expansion.

If you were hoping for a “we’ll cut costs aggressively” call, you’re in the wrong room. Ajanta is spending—on people, products, and pipelines—without losing profitability.

Read on. Because beneath the dividend cheer lies a carefully engineered growth machine… with a few pressure points.

2. At a Glance

Revenue up 14%: ₹1,354 cr Q2 sales—boringly consistent, exactly how management likes it.
EBITDA margin ~27% (ex-FX): Expenses rose, margins didn’t panic.
PAT up 20%: Profits clearly got the growth memo.
US business +48%: Suddenly the star performer, no FDA horror stories attached.
Dividend ₹28/share: ₹350 cr returned—balance sheet says “we can afford this.”
Receivables at 101 days: Management calls it strategy, not stress.

3. Management’s Key Commentary

“The Board has approved an interim dividend of ₹28 per share.”
(Translation: Cash flows are healthy, confidence is healthier 😎)

“Revenue grew 14% with margins remaining resilient.”
(Translation: Inflation tried, Ajanta shrugged.)

“Asia contributed 40% of revenue and remains a strategic focus.”
(Translation: Slow and steady, not flashy.)

“US generic business grew 48% driven by new launches.”
(Translation: Timing finally worked, execution didn’t mess up.)

“Africa institutional business remains unpredictable.”
(Translation: Aid agencies still enjoy surprises.)

“We will invest aggressively in people and products.”
(Translation: Don’t expect margin expansion fireworks anytime soon.)

4. Numbers Decoded

Source table

Metric	Q2 FY26	Reality Check
Revenue	₹1,354 cr	Clean double-digit growth
Gross Margin	77%	Pricing power intact
EBITDA Margin	24% (27% ex-FX)	FX accounting playing spoilsport
PAT	₹260 cr	Growth outpacing revenue
ROCE	33%	Capital efficiency still elite
Capex (H1)	₹145 cr	Expansion mode fully on

One-liner: High-margin pharma still printing cash—just spending more of it upfront.

5. Analyst Questions

Low India launches? Management says “selective,” not lazy—only launching where conviction exists.
US sustainability? Management confident current run-rate

To Read Full 16 Point